Last Price$394.92.3%
Market Cap$150.5B
10.2%
Peers median - 3.1%
15.4%
Peers median - 14.8%
28.4%
Peers median - 37.2%
14.6%
Peers median - 11.2%
Competing with SYK
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$150.5B | 6.6 | $305.1 22.7% overvalued | 12.0% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 14.6% | 28.4% | |
$242.4B | 7.0 | $174.5 24.5% undervalued | 19.2% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$154.5B | 6.7 | $34.2 67.4% overvalued | 55.5% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$120.9B | 6.2 | $114.6 21.5% undervalued | 14.7% | $33.2B | $5,467.0M | 2.7% | 16.5% | 52.7% | 7.4% | 53.6% | |
$43.4B | 6.1 | $54.1 24.2% overvalued | (18.0%) | $5,872.6M | $502.2M | 0.9% | 8.6% | 77.8% | 25.8% | 7.4% | |
$34.9B | 7.0 | $43.1 49.8% overvalued | (29.7%) | $4,033.0M | $453.9M | 11.3% | 11.3% | 60.4% | 21.7% | 120.3% | |
$24.7B | 5.3 | $65.0 146.8% undervalued | 34.0% | €18.0B | €274.0M | (0.8%) | 1.5% | 43.1% | (4.2%) | 63.4% | |
$21.9B | 6.2 | $199.6 10.4% overvalued | (3.8%) | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 1.9% | |
$21.6B | 5.9 | $181.2 72.0% undervalued | (15.3%) | $5,655.4M | $1,132.4M | (23.5%) | 20.0% | 64.3% | 4.5% | 43.0% | |
$19.4B | 7.9 | $134.5 50.7% overvalued | 62.5% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 29.7% | 6.9% | |
$13.6B | 6.0 | $190.0 8.5% undervalued | (43.2%) | $3,999.0M | $622.7M | 3.5% | 15.6% | 70.3% | 14.2% | 2.3% |
Compare SYK Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Stryker CorporationSYK
7.0x
10.2%
(5.8%)
13.2%
Median Peer Set
5.4x
4.1%
126.3%
11.8%
Abbott LaboratoriesABT
5.9x
4.6%
134.5%
31.9%
Align Technology, Inc.ALGN
3.2x
3.4%
26.0%
11.5%
Boston Scientific CorporationBSX
9.9x
17.6%
16.7%
11.1%
DexCom, Inc.DXCM
8.6x
11.3%
(1.4%)
14.3%
Edwards Lifesciences CorporationEW
6.8x
(9.4%)
202.2%
76.7%
Medtronic plcMDT
4.4x
3.6%
(2.1%)
11.4%
Koninklijke Philips N.V.PHG
1.6x
(0.8%)
118.1%
(3.9%)
Insulet CorporationPODD
9.7x
30.0%
4,364.6%
12.2%
STERIS plcSTE
4.1x
3.6%
257.9%
7.4%
Zimmer Biomet Holdings, Inc.ZBH
4.8x
6.5%
253.2%
13.8%
Compare SYK Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Stryker Corporation (SYK) revenue growth compare to peers and the industry?
Stryker Corporation (SYK) revenue growth is 10.2%, compared to the peers' median of 3.1%.
2. How does Stryker Corporation (SYK) Free Cash Flow (FCF) margin compare to peers and the industry?
Stryker Corporation (SYK) FCF margin is 15.4%, compared to the peers' median of 14.8%.
3. How does Stryker Corporation (SYK) Total Debt to Equity ratio compare to peers and the industry?
Stryker Corporation (SYK) Total Debt to Equity ratio is 28.4%, compared to the peers' median of 37.2%.
4. How does Stryker Corporation (SYK) ROIC (Return on Invested Capital) compare to peers and the industry?
Stryker Corporation (SYK) ROIC is 14.6%, compared to the peers' median of 11.2%.